title: A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.
authors.forename: M
authors.initials: M
authors.lastname: Caproni
authors.forename: W
authors.initials: W
authors.lastname: Volpi
authors.forename: C
authors.initials: C
authors.lastname: Chiarini
authors.forename: E
authors.initials: E
authors.lastname: Antiga
authors.forename: B
authors.initials: B
authors.lastname: Giomi
authors.forename: P
authors.initials: P
authors.lastname: Fabbri
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects*; D008218:Lymphocytosis / Q000139:chemically induced*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab